Cortellis Drug Discovery Intelligence
Accelerate R&D with drug discovery and preclinical intelligence
Drug discovery analytics for biopharma and academia
With 88% of drugs entering clinical stages predicted to fail, leveraging trusted multi-source preclinical drug development data is essential to bridge target-disease gaps, minimize late-stage setbacks, and reduce costly trial failures.
Benchmark and improve your drug candidates
Identify key targets and biomarkers
Strengthen preclinical programs
A drug discovery platform built for scientists, by scientists
Reliable, enriched data
Access accurate, timely preclinical drug discovery data curated through advanced technology and expert scientific review to support confident decisions.
Granular indexing
Search by drug , disease, chemical structure and more, and drill down to the answers you need with 20+ filters and granular indexed data.
Broad and deep coverage
Unmatched breadth of scientific intelligence, covering global sources and spanning 27+ therapy areas and 6500+ diseases, including rare.
Dynamic visualizations
Inform drug repurposing and indication prioritization with target-disease relationship scoring and visualizations of disease mechanisms.
Assay and model benchmarking
Select optimal assays, explore advanced disease models, and explore organ-on-chip and organoid systems to reduce reliance on animal testing.
Integrated insights
Gain visibility from target to treatment, with direct links to drug safety and trial design intelligence via the unified Cortellis family.
Leverage the most comprehensive drug discovery database
Make informed go/no-go decisions
Tap into critical R&D data to make confident indication prioritization and drug repurposing decisions and efficiently move drugs through development. Confirm the link between target and indication and connect all related information with a leading drug discovery platform.
Benchmark drugs’ experimental performance
Understand who is developing drugs like yours and compare experimental performance to better assess your competitors. Use previous research to make informed go/no-go decisions regarding your pipeline or design your experiments.
Understand metabolic pathways
Explore active metabolites and uncover desired pharmacological or off-target activity in humans and animal models. Evaluate competitor drug activity in vitro and in vivo and identify the best assays to test the efficacy of your molecules.
Speed up compound synthesis
Conduct structure searches of your compounds to uncover similar compounds and related synthesis schemes, including intermediates. Benchmark drug candidates based on pharmacology and pharmacokinetics to identify competitive strengths and weaknesses.
Make confident R&D decisions and avoid late-stage failures with curated preclinical drug development intelligence
804k+
47k+
222k
53k+
695k+
1.7m+
Resources
Assessing the potential of PROTACs as treatments for Alzheimer's disease
PROteolysis TArgeting Chimeras (PROTACs) represent a promising class of drugs designed to degrade disease-causing proteins by leveraging the ubiquitin-proteasome system. The PROTAC field is rapidly evolving, with numerous companies and…
Frequently asked questions
Find answers to common questions about our drug discovery database, from data sources and coverage to key benefits.
Cortellis Drug Discovery Intelligence is a comprehensive platform that centralizes biological, chemical, and pharmacological data from global sources. It empowers researchers to accelerate drug development by providing integrated, expert-curated intelligence across the entire drug lifecycle.
Cortellis Drug Discovery Intelligence delivers unmatched depth and breadth of expert-curated data, bringing biological, chemical, and pharmacological insights together in one platform. Quickly connect the dots between disease, targets, drugs, and biomarkers, and access validated details on patents, mechanisms of action, experimental models, and safety profiles to accelerate confident go / no go decisions.
Cortellis Drug Discovery Intelligence is trusted by leading pharmaceutical companies, biotechs, academic research centers, contract research organizations (CROs), and government/public health agencies. It supports all R&D roles, including executives, biologists, pharmacologists, medicinal chemists, biomarker scientists, and translational researchers.
Explore the competitive drug development landscape with curated insights into emerging molecules, patent filings, and competitor pipelines. Prioritize high-potential targets, identify strategic opportunities early, and conduct thorough scientific due diligence on competitors, enabling faster differentiation.
Accelerate target discovery and validation to advance the most promising therapies with clarity and speed. Prioritize and assess potential drug targets using expert-curated target-disease scoring, visualize mechanistic pathways, and connect all relevant data to understand the biological rationale behind a disease or biological process.
Cortellis Drug Discovery Intelligence enables lead compound optimization by assessing structure-activity relationships and predicting efficacy and safety profiles. The platform’s curated data on chemical structures, pharmacokinetics, and experimental models helps refine drug candidates and reduce late-stage failures.
Biomarker scientists can quickly link biomarkers to drugs, diseases, and targets, as well as their uses, to evaluate their potential for diagnosing diseases or assessing the effectiveness of treatments.
Cortellis Drug Discovery Intelligence provides you with an integrated source of biological, chemical, and pharmacological data from disparate sources into a single drug discovery platform. Our team of scientific experts select and curate data from the following sources:
- 1500+ scientific journals
- 160+ international conferences
- 7 main patent offices
- Regulatory agencies (FDA, EMA, PMDA & TGA)
- ClinicalTrials.gov
- Pharma & biotech company web pages
Yes. Expert-curated insights from Cortellis Drug Discovery Intelligence are cited in numerous peer-reviewed publications from leading universities and pharmaceutical R&D teams. Dozens of manuscripts have used Cortellis Drug Discovery Intelligence data to support discoveries in fields such as oncology, immunology, and rare diseases—helping researchers turn hypotheses into evidence.
Drug and target safety insights are provided through the combined power of Cortellis Drug Discovery Intelligence and OFF-X Translational Safety Intelligence. Together, they deliver a holistic solution for drug development. Cortellis Drug Discovery Intelligence offers comprehensive biological, chemical, and pharmacological data, while OFF-X adds expert-curated drug safety intelligence. This synergy helps researchers anticipate risks early and confidently advance compounds from lab to clinic.
Yes, you can leverage bulk data from this drug discovery database as a data feed or API to populate internal data and analytics solutions.
